46.70
Crispr Therapeutics Ag stock is traded at $46.70, with a volume of 2.68M.
It is down -2.01% in the last 24 hours and up +26.70% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$47.66
Open:
$47.33
24h Volume:
2.68M
Relative Volume:
1.24
Market Cap:
$3.71B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-16.68
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
+5.11%
1M Performance:
+26.70%
6M Performance:
+13.71%
1Y Performance:
-17.53%
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CRSP
Crispr Therapeutics Ag
|
46.70 | 3.71B | 170.10M | -239.59M | -191.20M | -2.80 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
Feb-03-25 | Initiated | H.C. Wainwright | Buy |
Aug-06-24 | Reiterated | Needham | Buy |
Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
Jun-28-24 | Resumed | Guggenheim | Neutral |
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-27-23 | Initiated | Mizuho | Buy |
Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
May-30-23 | Initiated | William Blair | Outperform |
Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
Mar-21-23 | Initiated | Bernstein | Mkt Perform |
Mar-17-23 | Initiated | Bryan Garnier | Buy |
Mar-07-23 | Initiated | Robert W. Baird | Neutral |
Oct-11-22 | Initiated | Morgan Stanley | Underweight |
Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Apr-28-22 | Initiated | Credit Suisse | Neutral |
Dec-07-21 | Initiated | Cowen | Market Perform |
Oct-19-21 | Initiated | SVB Leerink | Outperform |
Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
Dec-10-20 | Reiterated | Needham | Buy |
Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
Oct-05-20 | Initiated | BofA Securities | Buy |
Jul-28-20 | Reiterated | Needham | Buy |
Jul-14-20 | Initiated | SunTrust | Buy |
Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
Mar-05-20 | Initiated | Stifel | Hold |
Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
Aug-01-19 | Initiated | Jefferies | Buy |
Jul-26-19 | Initiated | Canaccord Genuity | Buy |
Jun-10-19 | Initiated | ROTH Capital | Buy |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Mar-14-19 | Initiated | William Blair | Mkt Perform |
Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Traders Buy High Volume of Call Options on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - MSN
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
CRISPR Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo
Citizens JMP reiterates CRISPR Therapeutics stock rating on in-vivo progress - Investing.com
SG Americas Securities LLC Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpShould You Buy? - MarketBeat
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
25,341 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Avanza Fonder AB - MarketBeat
Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million? - 24/7 Wall St.
Millennium Management LLC Trims Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Equities Analysts Set Expectations for CRSP FY2026 Earnings - MarketBeat
Crispr extends gains for the seventh consecutive trading day - MSN
Crispr Therapeutics: Betting On A One-Shot Future (NASDAQ:CRSP) - Seeking Alpha
Trend Tracker for (CRSP) - news.stocktradersdaily.com
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6%Here's What Happened - MarketBeat
Crispr Therapeutics AG: Stock Soars Amid Bullish Trends - MSN
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance
Crispr Therapeutics: Early-Stage Research Updates Show Promise (NASDAQ:CRSP) - Seeking Alpha
Cantor Fitzgerald Weighs in on CRSP FY2026 Earnings - Defense World
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts - Yahoo Finance
Crispr Therapeutics (CRSP) Rallies Amid FDA Fast-Tracking News - GuruFocus
Crispr extends gains for the seventh consecutive trading day (CRSP:NASDAQ) - Seeking Alpha
CRISPR Therapeutics AG shareholders approve key proposals By Investing.com - Investing.com South Africa
CRISPR Therapeutics AG Shareholders Approve Key Proposals - TipRanks
CRISPR Therapeutics AG shareholders approve key proposals - Investing.com
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It - Benzinga
Wealth Enhancement Advisory Services LLC Has $1.08 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - MSN
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month - simplywall.st
Crispr: Shares Very Undervalued, as Early-Stage Pipeline Makes Progress and Casgevy Launch Underway - Morningstar
CRSP Sees Significant Increase in Bullish Option Activity | CRSP Stock News - GuruFocus
Crispr Therapeutics call volume above normal and directionally bullish - TipRanks
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Raised by Green Alpha Advisors LLC - MarketBeat
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - sharewise
Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG - TipRanks
Can CRISPR Build On Casgevy's Success With Its In Vivo Pipeline? - Barchart.com
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Voloridge Investment Management LLC - MarketBeat
Capital Market Strategies LLC Buys 9,652 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Q2 EPS Forecast for CRISPR Therapeutics Increased by Analyst - MarketBeat
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crispr Therapeutics Ag Stock (CRSP) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Kulkarni Samarth | Chief Executive Officer |
Mar 21 '25 |
Sale |
41.23 |
10,031 |
413,578 |
195,085 |
Bruno Julianne | Chief Operating Officer |
Mar 21 '25 |
Sale |
41.23 |
1,714 |
70,668 |
10,544 |
Prasad Raju | Chief Financial Officer |
Mar 21 '25 |
Sale |
41.23 |
2,197 |
90,582 |
16,767 |
KASINGER JAMES R. | General Counsel and Secretary |
Mar 21 '25 |
Sale |
41.23 |
3,185 |
131,318 |
81,729 |
Prasad Raju | Chief Financial Officer |
Mar 17 '25 |
Sale |
41.80 |
3,762 |
157,252 |
12,714 |
Kulkarni Samarth | Chief Executive Officer |
Mar 11 '25 |
Sale |
42.42 |
9,973 |
423,055 |
180,890 |
Kulkarni Samarth | Chief Executive Officer |
Mar 12 '25 |
Sale |
43.32 |
4,462 |
193,294 |
185,428 |
KASINGER JAMES R. | General Counsel and Secretary |
Mar 11 '25 |
Sale |
42.42 |
2,850 |
120,897 |
77,530 |
KASINGER JAMES R. | General Counsel and Secretary |
Mar 12 '25 |
Sale |
43.32 |
1,116 |
48,345 |
78,664 |
Bruno Julianne | Chief Operating Officer |
Mar 11 '25 |
Sale |
42.42 |
1,198 |
50,819 |
8,263 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):